|
Cancer
research in India: Opportunities and obstacles
The union government's amendment to Schedule Y of the Drugs
and Cosmetics Act and formulation of progressive policies
has given a fillip to clinical research in the country, especially
in the field of oncology. Although as far as drug discovery
is concerned India has has miles to go, it is doing remarkably
well on the operational research front says Sapna Dogra.
In
search of NDDS
Suresh D and Gupta VB suggest an alternative to oral drug
delivery—colon targeted drug delivery system, its intricacies
and complexities.
Inhale
your insulin
Exubera, a trademark of Pfizer and Sanofi-Aventis, may be
the answer to diabetics' prayer for an alternative method
of delivery to insulin injections. Deepali Gupta reports.
|
